Drug Combination Details
| General Information of the Combination (ID: C87786) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | PFK15 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PFKFB3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
| OPM-2 | CVCL_1625 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3. Biochem Biophys Res Commun. 2019 Jul 23;515(2):332-338. | |||
